Active variants of FGF with improved specificity
US7288406B2 · kind B2 · utility
100Cited by
8References
22Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Apr 29, 2003 |
| Grant date | Oct 30, 2007 |
| Priority date | — |
| Expiry date | Sep 18, 2024 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61P35/00
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention provides active fibroblast growth factor variants demonstrating enhanced receptor subtype specificity. The preferred novel variants retain binding to FGF Receptor Type 3 (FGFR3) triggering intracellular downstream mechanisms leading to activation of a biological response. Methods of utilizing preferred FGF mutants in preparation of medicaments for the treatment of malignancies and skeletal disorders including osteoporosis and enhancing fracture healing and wound healing processes are provided.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.